59839-23-5

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR
• Synonyms: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR;1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HYDROBROMIDE;1,2,3,4-Tetrahydroisoquinolin-6-olhydrobrimide;l,2,3,4-Tetrahydro-6-isoquinolinol Hydrobromide;1,2,3,4-Tetrahydro iso-6-hydroxy-quinoline HBr;1,2,3,4-Tetrahydro-iso-6-hydroxy-quinoline HBr;6-HYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE HBR;1,2,3,4-tetrahydro-6-hydroxy-isoquinoline-hydrobroMide
• CAS NO: 59839-23-5
• Molecular Formula: BrH*C₉H₁₁NO
• Molecular Weight: 230.10168
• Product Categories: Quinoline&Isoquinoline
• Mol File: 59839-23-5.mol
• Article Data: 19

Chemical Properties

• Melting Point: 196.7-197.8℃
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR(59839-23-5)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-6-OL HBR(59839-23-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 59839-23-5(Hazardous Substances Data)

Usage

Description

1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide (HBr) is an organic compound that serves as a crucial chemical reagent in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which allows it to participate in a range of chemical reactions and contribute to the development of different therapeutic agents.

Uses

Used in Pharmaceutical Industry:
1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide is used as a chemical reagent for the preparation of androgen receptor modulators (SARMs). These compounds are designed to selectively target androgen receptors, offering potential therapeutic benefits for conditions related to muscle wasting, osteoporosis, and other disorders.
1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide is also used as a chemical reagent in the synthesis of steroidmimetic compounds. These molecules mimic the structure and function of steroid hormones, which can be utilized in the development of drugs targeting various medical conditions, including inflammation, immune disorders, and hormonal imbalances.
Furthermore, 1,2,3,4-Tetrahydro-isoquinolin-6-ol hydrobromide is employed in the preparation of chimeric microtubule disruptors. These compounds are designed to interfere with the normal function of microtubules, which are essential components of the cellular cytoskeleton. By disrupting microtubule function, these chimeric compounds can inhibit cell division and proliferation, making them potential candidates for cancer therapy.

InChI:InChI=1/C9H11NO.BrH/c11-9-2-1-8-6-10-4-3-7(8)5-9;/h1-2,5,10-11H,3-4,6H2;1H

Upstream product

• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 942150-85-8 bis(6-methoxy-N-1,2,3,4-tetrahydroisoquinolinyl)methane 
• 3179-09-7 1-methoxy-3-(2-nitrovinyl)benzene 
• 591-31-1 3-methoxy-benzaldehyde 
• 541-41-3 chloroformic acid ethyl ester 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 57196-62-0 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 860436-57-3 tert-butyl 6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 

Downstream Products

• 800373-89-1 (6-hydroxy-3,4-dihydro-1H-isoquinolin-2-yl)-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methanone 
• 94085-74-2 6-hydroxy-2-(3-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1623785-67-0 2-(3-chloro-4,5-dimethoxybenzyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1623785-72-7 2-(3-chloro-4,5-dimethoxybenzoyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1623785-69-2 2-(3,5-dimethoxy-4-ethoxybenzyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1623785-73-8 2-(3,5-dimethoxy-4-ethoxybenzoyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1064206-24-1 6-hydroxy-2-(3,4,5-triethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064205-97-5 6-hydroxy-2-(3,4,5-triethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline 
• 1623785-68-1 2-(3-bromo-4,5-dimethoxybenzyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1064206-28-5 6-hydroxy-2-(3,4,5-trimethoxyphenethyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064205-77-1 6-hydroxy-2-(3,4,5-trimethoxyphenacetyl)-1,2,3,4-tetrahydroisoquinoline 
• 1623785-70-5 6-hydroxy-2-(3,4,5-trimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline 
• 1064200-16-3 2-(3,5-dimethoxybenzoyl)-6-O-sulfamoyl-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION

Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS

The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related di

Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors

A structure-activity relationship (SAR) translation strategy was used for the discovery of tetrahydroisoquinoline (THIQ)-based steroidomimetic and chimeric microtubule disruptors based upon a steroidal starting point. A steroid A,B-ring-mimicking THIQ core was connected to methoxyaryl D-ring ring mimics through methylene, carbonyl and sulfonyl linkers to afford a number of steroidomimetic hits (e.g., 7-methoxy-2-(3- methoxybenzyl)-6-sulfamoyloxy-1,2,3, 4-tetrahydroisoquinoline (20 c) GI50=2.1 μM). Optimisation and control experiments demonstrate the complementary SAR of this series and the steroid derivatives that inspired its design. Linkage of the THIQ-based A,B-mimic with the trimethoxyaryl motif prevalent in colchicine site binding microtubule disruptors delivered a series of chimeric molecules whose activity (GI50=40 nM) surpasses that of the parent steroid derivatives. Validation of this strategy was obtained from the excellent oral activity of 7-methoxy-6-sulfamoyloxy-2-(3,4,5-trimethoxybenzyl)-1,2,3,4- tetrahydroisoquinoline (20 z) relative to a benchmark steroidal bis- sulfamate Copyright